At a glance
ClinicalIndex Comparison RecordN/ACompleted· 97 enrolled
Drug / intervention
MHNA-003device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Open-Label Trial of MHNA-003, a Smartphone-Delivered Cognitive Behavioral Therapy (CBT) Treatment, in Adults With Symptoms of Tinnitus
In Brief
A clinical study evaluating MHNA-003 for Tinnitus. Completed, enrolled 97 participants across 1 site.
Detailed Summary
The main objective of this prospective, open-label, non-significant risk study is to assess the efficacy and safety of Mahana™ Tinnitus together with care as usual in approximately 250 adults with symptoms of tinnitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTinnitus
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartDec 2022
First PostedJan 2023
Primary CompletionAug 2023
TodayJul 2026
First PostedJan 25, 2023
Enrollment StartDec 19, 2022
Primary CompletionAug 2, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.4 years ago
Interventions
MHNA-003device
MHNA-003 is a self-guided digital program for people living with tinnitus